Program Description

Program Description

The Heart in Diabetes (HiD) conference, entering its fifth year, is a unique medical meeting that brings world-renowned clinical leaders in diabetes and cardiovascular disease and practicing clinicians together to improve the care of patients at a high risk of cardiovascular, metabolic, and kidney diseases.

 

HiD 2021 will be held at the Sheraton Times Square Hotel in New York City on September 10-12 and will present a Hybrid Meeting - a combination of Live-in person event with a component of Live Streaming Webinar followed by 90 days on demand.

 

This is a CME meeting where participants can earn up to 24.25 CME & ABIM-MOC credits.

 

This program is designed to evaluate the clinical science aspects of diabetes, obesity, and CVD, focusing on the heart and kidney in diabetes. The goal is to develop appropriate comprehensive clinical management plans aligning endocrinologists, cardiologists, nephrologists and all other interested clinicians in their understandings of the impact of diabetes and CVD outcome trials on the clinical management of these very high-risk patients.

Upon completion of this meeting, participants should be able to:

  • Evaluate the evidence supporting the use of SGLT2 inhibitors to reduce CKD, HF, and cardiovascular disease and mortality in patients with T2D

  • Discuss the role of incretins in the management of obesity, diabetes, and their complications

  • Evaluate the extent of vascular disease in diabetes, obesity, and cardiometabolic syndrome

  • Provide comprehensive management of diabetes, addressing obesity, dyslipidemia as well as hyperglycemia

  • Discuss changes in lipid management guidelines

  • Evaluate the impact of CVOTs on guidelines and clinical practice

  • Describe optimal use of technology, specifically CGM and its impact on diabetes and CVD

  • Describe the state of heart disease in women

  • Discuss diabetes, CKD, CVD, and HF in diverse populations

  • Describe how to assess CV risk in DM with imaging and Biomarkers

  • Recognize the role of sleep apnea in diabetes and CVD

  • State contemporary management modalities of ASCVD risk in Diabetes 

  • Recognize the implication of diabetes and CVD on the severity of COVID-19

  • Discuss the difference of the new Non steroidal MRA and its effect on CKD in Diabetes

Initiative/Goal
  • To develop a platform to address the clinical science of the Heart in Diabetes

  • To identify the implications of state-of-the-art clinical research on cardiovascular, liver, and kidney disease in diabetes

  • To further advance the discussion between Cardiologists, Endocrinologists, Nephrologists, Lipidologists, and other interested clinicians, while developing an ongoing interaction in the management and prevention of heart disease in diabetes and cardiometabolic conditions

Target Audience

This educational initiative is designed for endocrinologists, cardiologists, diabetologists, nephrologists, internists, family physicians, nurse practitioners, physician assistants, and other healthcare professionals interested in the prevention and treatment of diabetes, obesity, cardiovascular disease, and associated conditions, as well as the effect of these conditions on health and society.

*As we approach the conference, TMIOA/HiD teams are closely monitoring COVID-19 Guidelines for the Sheraton Hotel and NYC. Please contact info@tmioa.com if you have any questions or concerns.